STOCK TITAN

PUMA BIOTECHNOLOGY INC - PBYI STOCK NEWS

Welcome to our dedicated page for PUMA BIOTECHNOLOGY news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on PUMA BIOTECHNOLOGY stock.

Puma Biotechnology Inc (PBYI) is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative treatments for cancer. Specializing in the in-licensing of drug candidates, Puma focuses on therapies that have undergone initial clinical testing, aiming to advance these candidates for commercial use. The company's core mission is to enhance cancer care and improve patient outcomes through cutting-edge treatments.

One of Puma Biotechnology's flagship products is NERLYNX, an oral version of neratinib. This drug is specifically designed for the treatment of HER2-positive breast cancer. NERLYNX works by inhibiting the HER2 receptor, which plays a key role in the growth and spread of breast cancer cells. The effectiveness and commercial success of NERLYNX highlight Puma's commitment to providing innovative solutions in oncology.

In addition to NERLYNX, Puma is developing alisertib, a selective inhibitor of aurora kinase A. This small-molecule drug disrupts mitosis, leading to the apoptosis of rapidly proliferating tumor cells. Alisertib is targeted at various forms of cancer, making it a versatile addition to Puma's portfolio.

Puma Biotechnology's strategy involves collaboration and partnerships to bring their innovations to market. The company has a robust financial foundation, enabling it to invest in research and development while pursuing effective commercialization strategies. Puma's ongoing projects and recent achievements demonstrate its role as a significant player in the biopharmaceutical industry, consistently pushing the boundaries of cancer treatment.

For investors and stakeholders, Puma Biotechnology's focus on innovative cancer therapies and its strategic development pipeline offer promising opportunities. The company's commitment to enhancing treatment outcomes ensures it remains at the forefront of the biopharmaceutical sector.

Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) announced the approval of an inducement restricted stock unit award for a new non-executive employee. The award, covering 7,500 shares of Puma common stock, was granted under the company's 2017 Employment Inducement Incentive Award Plan. The stock units will vest over three years, with one-third vesting on December 1, 2025, and one-sixth vesting every six months thereafter, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) has initiated the ALISCA™-Breast1 Phase II trial of alisertib combined with endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer patients. The study will enroll up to 150 patients who have previously received CDK 4/6 inhibitors and at least two prior endocrine therapies. Patients will be randomized to receive alisertib at 30mg, 40mg, or 50mg doses. The trial's primary endpoints include objective response rate, duration of response, disease control rate, progression-free survival, and overall survival. Initial data is expected in 2025, with plans to discuss potential approval pathways with the FDA following trial outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
-
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) reported strong Q3 2024 financial results with total revenue of $80.5 million, including $56.1 million in product revenue from NERLYNX® and $24.4 million in royalty revenue. The company posted a net income of $20.3 million ($0.41 per share), up from $5.8 million in Q3 2023. Operating cash flow was $11.0 million, with cash and equivalents of $97 million. The company updated its full-year 2024 guidance, projecting net product revenue of $187-190 million and net income of $15-17 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) announced the approval of an inducement restricted stock unit award of 5,625 shares to a new non-executive employee. The award, granted under the company's 2017 Employment Inducement Incentive Award Plan, will vest over three years, with one-third vesting after the first year and one-sixth every six months thereafter, starting from November 1, 2024. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
-
Rhea-AI Summary

Puma Biotechnology (NASDAQ:PBYI) announced it will host a conference call on Thursday, November 7, 2024, at 1:30 p.m. PST/4:30 p.m. EST to discuss its third quarter 2024 financial results. Participants can join via phone using 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's website, with a replay accessible for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
conferences earnings
-
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City. Alan H. Auerbach, the company's Chairman, CEO, President, and Founder, will present an overview of Puma Biotechnology on Monday, September 9, at 3:00 p.m. EDT.

Investors and interested parties can access a live webcast of the presentation through the company's website at pumabiotechnology.com. The presentation will remain available on the website for 30 days after the event, providing an opportunity for those unable to attend the conference to gain insights into Puma Biotechnology's current status and future plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) has granted an inducement restricted stock unit award to a new non-executive employee. The award, approved on August 5, 2024, covers 3,500 shares of Puma common stock. This grant falls under Puma's 2017 Employment Inducement Incentive Award Plan, adopted on April 27, 2017. The award will vest over three years, with one-third vesting on August 1, 2025, and one-sixth vesting every six months thereafter, contingent on continued employment. This award is in compliance with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for the new employee to join Puma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
none
-
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) reported its Q2 2024 financial results. Product revenue from NERLYNX® sales was $44.4 million, down from $51.6 million in Q2 2023. The company reported a net loss of $4.5 million, or $0.09 per share, compared to net income of $2.1 million in Q2 2023. Non-GAAP adjusted net loss was $2.5 million. Total revenue for Q2 2024 was $47.1 million, including $2.7 million in royalty revenue. Operating costs were $49.3 million. The company ended the quarter with $96.8 million in cash and equivalents. Puma anticipates key milestones in the next 12 months, including the initiation of ALISCA™-Breast1 trial and interim data from ALISCA™-Lung1 trial. The company provided guidance for Q3 and full-year 2024, projecting net product revenue of $183-$190 million for the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.43%
Tags
-
Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) has announced a conference call to discuss its second quarter 2024 financial results. The call is scheduled for Thursday, August 1, 2024, at 1:30 p.m. PDT/4:30 p.m. EDT. Investors can access the call by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's website. The call replay will be archived on Puma's website for 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences earnings
Rhea-AI Summary

Puma Biotechnology announced that its Compensation Committee approved the grant of an inducement restricted stock unit (RSU) award covering 3,500 shares of common stock to a new non-executive employee. This decision was made on July 1, 2024, under its 2017 Employment Inducement Incentive Award Plan. The RSU award will vest over three years, with one-third of the shares vesting on the first anniversary, and one-sixth vesting every six months thereafter. This grant was made as an inducement material for the new employee according to Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none

FAQ

What is the current stock price of PUMA BIOTECHNOLOGY (PBYI)?

The current stock price of PUMA BIOTECHNOLOGY (PBYI) is $2.94 as of December 11, 2024.

What is the market cap of PUMA BIOTECHNOLOGY (PBYI)?

The market cap of PUMA BIOTECHNOLOGY (PBYI) is approximately 144.8M.

What does Puma Biotechnology Inc (PBYI) specialize in?

Puma Biotechnology specializes in developing and commercializing innovative cancer treatments, focusing on in-licensing drug candidates that have undergone initial clinical testing.

What is NERLYNX?

NERLYNX is an oral version of neratinib developed by Puma Biotechnology for the treatment of HER2-positive breast cancer.

What is alisertib?

Alisertib is a selective inhibitor of aurora kinase A, designed to disrupt mitosis and induce apoptosis in rapidly proliferating tumor cells.

What is Puma Biotechnology's approach to drug development?

Puma focuses on in-licensing innovative drug candidates, advancing their development through clinical testing, and eventually commercializing them for cancer treatment.

How does NERLYNX work?

NERLYNX inhibits the HER2 receptor, which is involved in the growth and spread of HER2-positive breast cancer cells.

What types of cancer is alisertib aimed at treating?

Alisertib is targeted at various forms of cancer due to its mechanism of disrupting mitosis in tumor cells.

Does Puma Biotechnology collaborate with other companies?

Yes, Puma Biotechnology engages in partnerships and collaborations to advance the development and commercialization of its drug candidates.

What are some recent achievements of Puma Biotechnology?

Recent achievements include the successful commercialization of NERLYNX and ongoing development of alisertib.

What is the company's financial condition?

Puma Biotechnology has a robust financial foundation, supporting its research and development initiatives and commercialization strategies.

Why is Puma Biotechnology significant in the biopharmaceutical industry?

Puma Biotechnology is significant due to its innovative cancer therapies, strategic development pipeline, and commitment to improving patient outcomes.

PUMA BIOTECHNOLOGY INC

Nasdaq:PBYI

PBYI Rankings

PBYI Stock Data

144.81M
38.59M
15.14%
67.8%
6.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ANGELES